arthritis

NICE have released a Final Appraisal Document (FAD) recommending Janssen’s tremfya (guselkumab) as a new option for treating active psoriatic arthritis (PsA) in adults who have not responded well to disease-modifying antirheumatic drug (DMARD) therapy or who cannot tolerate them.

The recommendation is only for patients if they have the following:

Abbvie’s RINVOQ (upadacitinib) drug, for the treatment of active psoriatic arthritis (PsA) in adults, has been approved for use in NHS Scotland by the Scottish Medicines Consortium.

Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.

The University of Glasgow and Eli Lilly and Company have entered into a research collaboration, across four diseases, worth £4.6 million.

The European Commission has awarded approval to Gilead and Galpagos for their oral JAK inhibitor Jyseleca (filgotinib) as a treatment for moderate to severe active rheumatoid arthritis, either as a monotherapy or in combination with methotrexate (MTX), in patients who have failed to respond or proved intolerant to at least one disease‑modifying anti‑rheumatic drug (DMARD).

The decision was made off the back of Phase 2 and 3 data drawn from 3,500 patients in which Jyseleca was shown to successfully halt the progression of structural joint damage, with durable efficacy over 52 weeks

AbbVie have announced that the European Commission (EC) have granted marketing authorisation for RINVOQ (upadacitnib). It’s a daily selective reversible JAK inhibitor for the treatment of adults with moderate to severe rheumatoid arthritis, who are intolerant of other similar drugs.

It may be used as a monotherapy or in combination with methotrexate.

The EC authorisation of RINVOQ is based on data from a Phase 3 trial which saw 4,400 patients participate.

The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation of the therapy, it has emerged.

The therapy was approved in combination with methotrexate (MTX) for the treatment of active rheumatoid arthritis in adult patients who have seen inadequate response with disease-modifying anti-rheumatic drugs (DMARDs), including MTX, and additionally in patients with severe, active and progressive forms of the disease who have not been previously treated with MTX or other DMARDs.

A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drug (DMARD)-naïve when compared to AbbVie's Humira.

 The Phase IIIb/IV SPIRIT-H2H study, 566 patients with active PsA demonstrates Taltz’s superiority over the world’s bestselling drug.

The year seems like it's running away as we come to the end of April. It's been a more tense period than usual in the industry as the Takeda-Shire saga has unfolded, and unsurprisingly, news related to the merger has dominated the headlines. That's reflected in our most popular articles this week, with three stories related to the tale.

Eli Lilly and Hanmi signed an exclusive licensing and collaboration agreement to develop the Bruton’s tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of various autoimmune and other diseases in 2015.

The deal was worth a potential $690 million in total but that hasn’t stopped Lilly showing every sign of ducking out of the deal early.